Recombinant Plasma Protein Therapeutics Market
Recombinant Plasma Protein Therapeutics Market Size, Share & Industry Analysis, By Product Type (Recombinant Coagulation Factors, Recombinant Human Serum Albumin, Recombinant Human C1 Esterase Inhibitor, Others), By Application (Hemophilia A, Hemophilia B, Von Willebrand Disease, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa): Share, Size, Outlook, and Opportunity Analysis, 2024-2031.
Market Overview:
The recombinant plasma protein therapeutics market is expected to develop at a 7.2% CAGR from 2024-2031. The market value is predicted to rise from USD XX billion in 2024 to USD YY billion in 2031. North America now dominates the market, accounting for the vast majority of worldwide sales. Key criteria include the expanding prevalence of bleeding disorders, advances in recombinant DNA technology, and a growing demand for safer and more effective therapeutic choices.
The market is expanding rapidly due to the rising prevalence of uncommon blood illnesses as well as the benefits of recombinant products over plasma-based proteins. Technological breakthroughs in protein engineering and expression systems are driving market growth, allowing for the development of new and superior recombinant plasma protein treatments.
Market Dynamics:
Market Trend: Shift towards extended half-life recombinant coagulation factors
A significant trend in the recombinant plasma protein therapeutics market is the increasing focus on developing extended half-life recombinant coagulation factors. These next-generation medications have enhanced pharmacokinetic characteristics, which allow for less frequent dosing and potentially better patient results. This trend is most noticeable in the treatment of haemophilia, where prolonged half-life components are changing patient care. For example, several of these medications have been demonstrated to maintain factor levels above 1% for 5-7 days with weekly dosing, as opposed to typical half-life products, which require 2-3 day dosing intervals. This tendency stems from a goal to increase patient quality of life and treatment regimen adherence. Major pharmaceutical corporations are making significant investments in this area, with many prolonged half-life medications already on the market and others in late-stage clinical trials. The use of these medicines is projected to increase as more long-term safety and efficacy data become available, potentially changing the competitive landscape of the recombinant coagulation factor market.
Market Driver: Increasing prevalence of bleeding disorders and rare plasma protein deficiencies
The increasing prevalence of bleeding disorders and rare plasma protein shortages is a major driver of the recombinant plasma protein therapies industry. Haemophilia, von Willebrand disease, and other uncommon coagulation disorders afflict millions of people worldwide, resulting in a significant and growing demand for recombinant plasma protein products. According to the World Federation of Haemophilia, haemophilia A affects around 1 in 10,000 people, while haemophilia B affects about 1 in every 50,000 male births. Furthermore, von Willebrand disease is predicted to impact up to 1% of the global population, with many instances going untreated. Increased diagnosis rates, combined with greater access to healthcare in poorer nations, are broadening the patient base for recombinant plasma protein therapies. Furthermore, rising awareness of rare plasma protein shortages, such as C1 esterase inhibitor deficiency, is increasing demand for specialised recombinant products. This growing patient base serves as a solid platform for market expansion, encouraging pharmaceutical companies to invest in the research and development of new and improved recombinant plasma protein therapies.
Market Restraint: High costs associated with recombinant plasma protein therapeutics
The high cost of recombinant plasma protein therapies remains a key impediment to wider use, particularly in emerging regions. Complex production methods, severe regulatory requirements, and considerable R&D investments all contribute to these products' high prices. For example, the annual cost of treating a severe haemophilia patient using recombinant factors can sometimes reach $300,000. These high costs can strain healthcare budgets and restrict access to treatment, particularly in areas with inadequate insurance coverage or underdeveloped healthcare systems. The cost burden is especially difficult for those with lifelong illnesses such as haemophilia, who require frequent infusions. While the long-term benefits of recombinant goods in terms of safety and efficacy are well known, the immediate cost consequences may result in slower adoption rates in price-sensitive sectors. This financial barrier has sparked debate over value-based pricing models and the need for more cost-effective manufacturing procedures to allow more access to these life-saving medications.
Segment Overview:
Recombinant coagulation factors dominate the market, driven by their critical role in managing hemophilia and other bleeding disorders.
Recombinant coagulation factors now have the biggest market share in the recombinant plasma protein therapies category. This dominance can be attributed to their critical role in addressing haemophilia and other bleeding disorders, as well as ongoing advances in factor replacement therapy. These medications, which comprise recombinant factor VIII, factor IX, and von Willebrand factor, have transformed the treatment of bleeding disorders by providing safer and more consistent therapeutic choices than plasma-based therapies.
Recombinant coagulation factors are becoming increasingly common as a result of technological breakthroughs. For example, the development of prolonged half-life factors has greatly improved haemophilia therapy regimens. According to a New England Journal of Medicine study, extended half-life factor VIII products can keep factor levels over 1% for up to 5 days in some patients, compared to 48-72 hours with regular recombinant products.
Furthermore, the rising applications of recombinant coagulation factors outside of haemophilia contribute to their market domination. These medicines are increasingly being used in surgical settings for patients suffering from coagulation abnormalities, as well as for the treatment of acquired haemophilia. A retrospective investigation published in the Journal of Thrombosis and Haemostasis discovered that recombinant factor VIIa effectively controlled bleeding in 90% of surgical procedures in patients with factor VIII or IX inhibitors.
Regional Outlook:
North America leads the recombinant plasma protein therapeutics market, driven by advanced healthcare infrastructure and high adoption rates of innovative biopharmaceuticals.
North America, specifically the United States, dominates the global recombinant plasma protein therapies industry. Several reasons contribute to the region's leadership, including a well-established healthcare system, high healthcare spending, and a large patient population with bleeding disorders and unusual plasma protein shortages.
The frequency of bleeding disorders in North America has been a key driver of market expansion. According to the Centres for Disease Control and Prevention (CDC), about 20,000 people in the United States have haemophilia, while von Willebrand disease affects up to 1% of the population. This vast patient base, combined with the region's high acceptance rate of modern biopharmaceuticals, has produced an opportune setting for recombinant plasma protein therapies.
Recent regulatory approvals have strengthened the market in North America. For example, the FDA's approval of many longer half-life recombinant factors has increased treatment choices for haemophilia patients. These approvals have enhanced market competitiveness while also driving innovation in the industry.
In terms of market share, North America was responsible for over 45% of the worldwide recombinant plasma protein therapies market in 2023. The United States, in particular, had the highest stake in the region, with a market value greater than $4 billion. The region's market is likely to remain dominant over the projection period, driven by continuous R&D activities and rising demand for personalised medicine techniques in rare illness care.
Competitive Intelligence:
The recombinant plasma protein therapies industry is fiercely competitive, with a few prominent competitors and several rising biotech startups. Market leaders including Novo Nordisk, Pfizer, and Takeda Pharmaceutical have large market shares due to their diverse product portfolios and strong R&D capabilities.
Novo Nordisk, a market leader, has maintained its position through ongoing innovation in haemophilia care. The company's NovoSeven (recombinant factor VIIa) and NovoEight® (recombinant factor VIII) products have found extensive adoption, contributing significantly to its market share. Novo Nordisk reported $7.9 billion in revenue from its haemophilia and other uncommon bleeding disorders portfolio in 2023.
Pfizer has also been an important player, notably since its acquisition of Wyeth, which added the ReFacto AF (recombinant factor VIII) product line to its portfolio. To maintain its competitive edge, the business has focused on developing next-generation haemophilia treatments, such as gene therapies.
Takeda Pharmaceutical, through its acquisition of Shire, has emerged as a key player in the recombinant plasma protein therapies business. Adynovate (extended half-life recombinant factor VIII) has had great market success. Takeda announced a 5% year-over-year increase in its uncommon haematology division in 2023, with revenue of $2.7 billion.
Emerging players such as BioMarin Pharmaceutical and Sanofi (by its acquisition of Bioverativ) are expanding their market share through novel product offerings and strategic alliances. BioMarin, for example, has been at the forefront of developing gene treatments for haemophilia A, with its product valoctocogene roxaparvovec demonstrating promising clinical outcomes.
The market has also seen a trend of consolidation, with larger pharmaceutical corporations purchasing smaller, more inventive biotech firms to broaden their product portfolios and technological capabilities. This tendency is likely to continue, potentially changing the competitive landscape in the future years.
Analyst Opinion:
The recombinant plasma protein therapeutics market is positioned for considerable growth and change in the future years, owing to technical advancements and an increased emphasis on personalised treatment methods for uncommon diseases. The transition to extended half-life products, as well as the potential for gene treatments, offer promising horizons that could transform the treatment of bleeding diseases.
However, market stakeholders must address the issue of high treatment costs in order to enable more access to these life-saving medicines, especially in emerging markets. Manufacturing process innovations and biosimilar development could play a critical role in lowering the cost of recombinant plasma protein treatments while maintaining efficacy.
A unique topic to keep an eye on is the possible combination of recombinant plasma protein therapies with digital health technologies. The development of smart injectable devices and mobile patient monitoring software has the potential to greatly enhance treatment compliance and outcomes. This combination of biotechnology and digital health has the potential to create new paths for patient care while also reshaping the market's competitive structure.
Major Players:
-
Novo Nordisk A/S
-
Pfizer Inc.
-
Takeda Pharmaceutical Company Limited
-
CSL Limited
-
Octapharma AG
-
Bayer AG
-
Biogen Inc.
-
Shire Plc (now part of Takeda)
-
Grifols, S.A.
-
BioMarin Pharmaceutical Inc.
Key Developments:
-
June 2023: Novo Nordisk received FDA approval for its extended half-life recombinant factor IX product for the treatment of hemophilia B, offering patients a once-weekly dosing option.
-
March 2024: BioMarin Pharmaceutical announced positive Phase 3 results for its gene therapy treatment for severe hemophilia A, potentially paving the way for a paradigm shift in hemophilia treatment.
1. INTRODUCTION
1.1. Market Definitions & Study Assumptions
1.2. Market Research Scope and Segment
1.3. Research Methodology
2. EXECUTIVE SUMMARY
2.1. Market Overview & Insights
2.2. Segment Outlook
2.3. Region Outlook
3. COMPETITIVE INTELLIGENCE
3.1. Companies Financial Position
3.2. Company Benchmarking—Key Players
3.3. Market Share Analysis -- Key Companies
3.4. Recent Companies Key Activities
3.5. Pricing Analysis
3.6. SWOT Analysis
4. COMPANY PROFILES (Key Companies List by Country) (Premium)
5. COMPANY PROFILES
5.1. Novo Nordisk A/S
5.2. Pfizer Inc.
5.3. Takeda Pharmaceutical Company Limited
5.4. CSL Limited
5.5. Octapharma AG
5.6. Bayer AG
5.7. Biogen Inc.
5.8. Shire Plc (now part of Takeda)
5.9. Grifols, S.A.
5.10. BioMarin Pharmaceutical Inc. (LIST NOT EXHAUSTIVE)
6. MARKET DYNAMICS
6.1. Market Trends
6.1.1. Shift towards extended half-life recombinant coagulation factors
6.1.2. Integration of digital health technologies in treatment monitoring
6.1.3. Growing focus on gene therapies for bleeding disorders
6.2. Market Drivers
6.2.1. Increasing prevalence of bleeding disorders and rare plasma protein deficiencies
6.2.2. Advancements in recombinant DNA technology
6.2.3. Rising demand for safer and more effective therapeutic options
6.3. Market Restraints
6.3.1. High costs associated with recombinant plasma protein therapeutics
6.3.2. Stringent regulatory requirements for biopharmaceuticals
6.4. Market Opportunities
6.5. Porter's Five Forces Analysis
6.5.1. Threat of New Entrants
6.5.2. Bargaining Power of Buyers/Consumers
6.5.3. Bargaining Power of Suppliers
6.5.4. Threat of Substitute Products
6.5.5. Intensity of Competitive Rivalry
6.6. Supply Chain Analysis
6.7. Value Chain Analysis
6.8. Trade Analysis
6.9. Pricing Analysis
6.10. Regulatory Analysis
6.11. Patent Analysis
6.12. SWOT Analysis
6.13. PESTLE Analysis
7. BY PRODUCT TYPE (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
7.1. Recombinant coagulation factors
7.1.1. Factor VIII
7.1.2. Factor IX
7.1.3. Von Willebrand Factor
7.1.4. Other factors
7.2. Recombinant Human Serum Albumin
7.3. Recombinant human C1 esterase Inhibitor
7.4. Others
8. BY APPLICATION (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH)--2020-2031)
8.1. Hemophilia A
8.2. Hemophilia B
8.3. Von Willebrand Disease
8.4. Others
9. BY DISTRIBUTION CHANNEL (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
9.1. Hospital Pharmacies
9.2. Retail Pharmacies
9.3. Online pharmacies
10. REGION (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
10.1. North America
10.1.1. United States
10.1.2. Canada
10.1.3. Mexico
10.2. South America
10.2.1. Brazil
10.2.2. Argentina
10.2.3. Rest of South America
10.3. Europe
10.3.1. Germany
10.3.2. United Kingdom
10.3.3. France
10.3.4. Italy
10.3.5. Spain
10.3.6. Russia
10.3.7. Rest of Europe
10.4. Asia-Pacific
10.4.1. China
10.4.2. Japan
10.4.3. India
10.4.4. Australia
10.4.5. South Korea
10.4.6. Rest of Asia-Pacific
10.5. Middle-East
10.5.1. UAE
10.5.2. Saudi Arabia
10.5.3. Turkey
10.5.4. Rest of Middle East
10.6. Africa
10.6.1. South Africa
10.6.2. Egypt
10.6.3. Rest of Africa
*NOTE: All the regions mentioned in the scope will be provided with (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%, YOY GROWTH)--2020-2031.
Recombinant Plasma Protein Therapeutics Market Segmentation:
By Product Type:
-
Recombinant coagulation factors
-
Recombinant Human Serum Albumin
-
Recombinant human C1 esterase inhibitor
-
Others
By Application:
-
Hemophilia A
-
Hemophilia B
-
Von Willebrand Disease
-
Others
By Distribution Channel:
-
Hospital Pharmacies
-
Retail pharmacies
-
Online pharmacies
By Region:
-
North America
-
Europe
-
Asia-Pacific
-
Latin America
-
Middle East & Africa
Frequently Asked Questions
We at Aurorawave Intellects Market Report gives total market analysis that suit our customer business need and permit decision maker to run organizations without any problem. We have accomplished greatness in giving start to finish market research arrangements. Our detachment of industry specialists accumulate key data and get ready substance that lines up with our customer's business/specialty.
We at aurorawaveintellects.com offer mainly 3 types of licenses:
• Single User: Research Report copy can be distributed to a single user only
• Multi User: Research Report distribution is restricted up to 5 users.
• Corporate License :Research Report can be distributed across the company.
Based on the nature of the topic or research, the formats vary. The different formats of the report are as following:
• Word Document
• PPT
Following modes are available for making the payment:
• Online Payment (Visa Card, Master Card, Stripe)
• Razorpay
• Net Banking
• Bank Wire Transfer
Our customer service and research specialist team are available by phone and by email. Customer service hours are 24X7 Indian Standard Time (IST). You may reach us at:
• Email: info@aurorawaveintellects.com
• United Kingdom: ++91 7382742511